Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. CCG and practice decile and extreme percentile (1–9, 91–99) time trends, 2011–17. This figure appears in ... Figure 1. CCG and practice decile.

Published byGrażyna Piątkowska Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1. CCG and practice decile and extreme percentile (1–9, 91–99) time trends, 2011–17. This figure appears in ... Figure 1. CCG and practice decile."— Presentation transcript:

1 Figure 1. CCG and practice decile and extreme percentile (1–9, 91–99) time trends, 2011–17. This figure appears in ... Figure 1. CCG and practice decile and extreme percentile (1–9, 91–99) time trends, 2011–17. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, Volume 74, Issue 4, 22 December 2018, Pages 1125–1132, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2. Interrupted time series analysis to determine the impact of the release of PHE guidance (left vertical line) ... Figure 2. Interrupted time series analysis to determine the impact of the release of PHE guidance (left vertical line) and the start of the QP monitoring period (right vertical line). Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, Volume 74, Issue 4, 22 December 2018, Pages 1125–1132, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3. Geographical variation for trimethoprim prescriptions as a proportion of total trimethoprim and ... Figure 3. Geographical variation for trimethoprim prescriptions as a proportion of total trimethoprim and nitrofurantoin prescriptions before and after the PHE guidance was amended and 6 months after the introduction of the QP. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, Volume 74, Issue 4, 22 December 2018, Pages 1125–1132, The content of this slide may be subject to copyright: please see the slide notes for details.

4 Figure 4. Mean trimethoprim prescriptions as a proportion of total trimethoprim and nitrofurantoin prescriptions in Figure 4. Mean trimethoprim prescriptions as a proportion of total trimethoprim and nitrofurantoin prescriptions in 10 highest and lowest CCGs, 2014–17. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, Volume 74, Issue 4, 22 December 2018, Pages 1125–1132, The content of this slide may be subject to copyright: please see the slide notes for details.

5 Figure 5. Proportion of trimethoprim prescribing 2012–18 in: (a) Nottingham North and East CCG; (b) North West Surrey ... Figure 5. Proportion of trimethoprim prescribing 2012–18 in: (a) Nottingham North and East CCG; (b) North West Surrey CCG; (c) Hastings and Rother CCG; and (d) Hillingdon CCG. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, Volume 74, Issue 4, 22 December 2018, Pages 1125–1132, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1. CCG and practice decile and extreme percentile (1–9, 91–99) time trends, 2011–17. This figure appears in ... Figure 1. CCG and practice decile."

Similar presentations

Figure 1. Direct evidence for the acquisition and demise of Tn6330 by DNA sequence alignment. (a) Comparison between ... Figure 1. Direct evidence for.

Figure 1. Direct evidence for the acquisition and demise of Tn6330 by DNA sequence alignment. (a) Comparison between ... Figure 1. Direct evidence for.
Figure 1. Distribution of ABCB1 SNVs and haplotypes.

Figure 1. Distribution of ABCB1 SNVs and haplotypes.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Figure 1. Colistin MIC distribution for the 153 colistin-resistant E

Figure 1. Colistin MIC distribution for the 153 colistin-resistant E
Figure 1. Variation in population size of the donor strain HN-1 and E

Figure 1. Variation in population size of the donor strain HN-1 and E
Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.

Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.
Figure 1. Structure of two poxtA-carrying plasmids in E

Figure 1. Structure of two poxtA-carrying plasmids in E
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1. Physician rankings from 0 to 100 in the odds of prescribing an antibiotic. The y-axis represents the null ... Figure 1. Physician rankings from.

Figure 1. Physician rankings from 0 to 100 in the odds of prescribing an antibiotic. The y-axis represents the null ... Figure 1. Physician rankings from.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Figure 1. SpeI-PFGE dendrogram comparing P

Figure 1. SpeI-PFGE dendrogram comparing P
Source: Figure created by the author based on data ...

Source: Figure created by the author based on data ...
bDMARD: biologic DMARD.

bDMARD: biologic DMARD.

Similar presentations

Ads by Google